secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001140361-25-032295
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics appoints Dan Weng, M.D. to Board of Directors
---------------------------------------------------------------

- Dan Weng appointed as Class II director effective August 18, 2025.
- Dr. Weng has extensive CRO leadership, including CEO of Medelis and former Chairman/CEO of EPS International.
- Appointment supported by parent company GNI Group Ltd. (TSE: 2160).
- He will receive standard non-employee director compensation per company policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125032295/0001140361-25-032295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125032295/ef20054243_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-032295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer